#### The Florida Senate

#### **COMMITTEE MEETING EXPANDED AGENDA**

BANKING AND INSURANCE Senator Broxson, Chair Senator Rouson, Vice Chair

MEETING DATE: Tuesday, November 5, 2019

**TIME:** 2:00—4:00 p.m.

PLACE: Pat Thomas Committee Room, 412 Knott Building

MEMBERS: Senator Broxson, Chair; Senator Rouson, Vice Chair; Senators Brandes, Gruters, Lee, Perry,

Taddeo, and Thurston

TAB	BILL NO. and INTRODUCER	BILL DESCRIPTION and SENATE COMMITTEE ACTIONS	COMMITTEE ACTION
	Presentations on the role of Pharmacy E	Benefit Managers in the Private Insurance Market	Presented
	Other Related Meeting Documents		

#### Shane Abbott, Pharm.D. Co-Owner, The Prescription Place in Defuniak Springs, FL

Shane Abbott is the co-owner of The Prescription Place, a locally owned, independent pharmacy in Defuniak Springs, FL. Upon graduation, Shane returned home to DeFuniak Springs, Florida to practice and provide care for family, friends and his community. In 2006 he and another local pharmacist opened and still co-own The Prescription Place.

Shane is a graduate of the University of Florida College of Pharmacy.

# Senate Banking & Insurance Committee

Tuesday, November 5, 2019

Presenter: Shane Abbott


The Prescription Place



# 15% Decrease in # of Independent Pharmacies in FL







Source: Quest Analytics analysis of NCPDP Pharmacy Count Data, 2019

# Decrease leads to...



Patients lose their local pharmacy



Patients have to drive out of their way to get their prescriptions



Often leads to an overall drop in medication adherence

# Problem stems from...





**Contracting Issues** 



Manipulative Steering



Arbitrary Payments



Debilitating Clawbacks

### Contracting



PSAOs are presented with take it or leave it contracts

Plan sends pharmacy direct contract that is take it or leave it

Non-negotiable contracts as a result of monopolies


Closed networks cause patient access issues and eliminate competition

Inefficient contract processes leave neighborhood pharmacies struggling to provide services for their patients

# Payments

SPAR

- Maximum Allowable Costs (MAC)
  - Same PBM uses several MACs
  - PBMs uses MAC to adjust profit margin to benefit themselves, not the patient
  - Currently subsidizing Medicaid



# Steering









- PBMs use letters, phone calls, and other incentives to convince patients to use their own pharmacy or mail order pharmacy
- Specialty drugs are required to be filled at their pharmacy only
- Frequently, this steering leads to patient compliance issues due to non-local access

# Clawbacks



- Independent pharmacies live in fear of fraudulent audits
- Independent pharmacies receive payments that are less than at the time of adjudication
  - In network fees
  - Out of network fees
  - Customer service fees
- Clawback money is being used to improve profit margins and not lower health care costs



### Focus On:



#### Most crucial factor that needs to be addressed is the reduced access for patients.

#### This can be accomplished through...

- No narrow networks for Medicaid
- No payment below cost of drug
- No steerage for PBM-owned pharmacies, mail order or specialty

- No POST adjudication fees
- No abusive audits with drug cost recoupment (other than fraud)

## Contact

#### **Shane Abbott**

**Prescription Place** 

1337 US Hwy 90 W

DeFuniak Springs, FL 32433

850-892-6898 prescriptionplace@yahoo.com



Small Business Pharmacies Aligned for Reform

#### Tom Brownlie, M.S. Senior Director, U.S. Policy, Pfizer Global Policy

Tom brings over 15 years of experience in various facets of the biopharmaceutical industry. Tom leads Pfizer's U.S. State Policy team and is responsible for developing and implementing coordinated national strategies to ensure Pfizer's policy strategies are patient-centered and align with enterprise-wide objectives. Tom's health policy expertise includes insurance benefit design, utilization management, drug pricing, the drug supply chain, prescription drug importation, health information technology (HIT), prescription drug abuse, Medicaid, Affordable Care Act implementation, and conflict of interest. Tom holds a Bachelor of Science in biology and nutrition, and a Master of Science in nutritional sciences, with minors in epidemiology and international nutrition, from Cornell University.


Pharmaceutical Supply Chain: Patient Impact

November 5, 2019





# Pharmaceutical Supply Chain



### Role of PBMs

# **Pharmacy Benefit Management Services**



Claims Processing



Price, Discount and Rebate Negotiations with Pharmaceutical Manufacturers and Drugstores



Formulary Management



Pharmacy Networks



Mail-service Pharmacy



Specialty Pharmacy



Drug Utilization Review



Disease Management and Adherence Initiatives

**APCMA** 

6

# List vs. Negotiated Price Growth



# **Spending Trend**





2018



1.2%




3.8%




**Annual Spending Growth** 

# Patient Cost-Sharing Trends




# Impact on Patients



#### Milliman Rebate Example:

- \$500 Rx List Price
- 40% Negotiated Rebate
- Patient deductible

# Impact on Patients



#### Milliman Rebate Example:

- \$500 Rx List Price
- 40% Negotiated Rebate
- 20% Patient Co-Insurance

# Thank you!





#### Tricia Fitzsimmons Director of Public Policy, Novartis

Tricia Fitzsimmons is the Director of Public Policy for Novartis focused on pricing policy and strategy. In her role, Tricia is responsible for developing policy positions and working with all U.S. Novartis businesses to assess the impact of federal and state legislative and administrative pricing proposals in the US healthcare system. Her prior pharmaceutical and biopharmaceutical industry experience includes commercial, managed care, and government pricing and contracting roles at Sandoz (a subsidiary of Novartis), Bayer Pharmaceuticals, and GE Healthcare Life Sciences.

Tricia has her Bachelor's Degree in Political Science and Government/Law and her Juris Doctor with a concentration in Healthcare and Pharmaceutical law from the Center for Health Law & Policy, Seton Hall University School of Law.

# Jacqueline Jacobi Regional Director of Pharmacy for Florida, New York and South Carolina, Molina Healthcare of Florida

Jacqueline Jacobi's passion for Pharmacy can be traced back to her first job working for an independent Pharmacy where she first experienced the true impact a Pharmacist could really make. Currently working as Regional Director of Pharmacy for Molina of Florida, New York and South Carolina is widely known for her strengths in Pharmacy Operations and her clinical expertise. Based in NY, Jackie, also does volunteering for Non for profit organizations and precepting for Pharmacy students in 2 of NY's Pharmacy schools.

# Molina Healthcare of Florida


Jacqueline Jacobi, RPH

Regional Director of Pharmacy for Florida, New York and South Carolina



### **Molina Healthcare of Florida**

- Molina Healthcare of Florida provides government-funded care for low-income individuals. Our mission is to provide quality health care to people receiving government assistance.
- We serve approximately 140,000 members through Medicaid, Medicare, and Health Insurance Marketplace programs.





# **Typical Services that PBMs Perform for MCOs**



Claims Processing



Price, Discount and Rebate Negotiations with Pharmaceutical Manufacturers



Formulary Management



Pharmacy Networks



Mail Service Pharmacy



Specialty Pharmacy



Drug Utilization Review



Disease Management and Adherence Initiatives



### How a MCO Selects a PBM: the RFP Process

#### PLAN ISSUES RFP

RFP dictates the terms and conditions of the PBM services that the client wants the PBM to perform and the way it wants to reimburse the PBM for the services it offers.

#### PBM BIDS

Clients typically
use benefit
consultants who
send the RPFs to
multiple PBMs—
the environment is
highly competitive.

# CLIENT DECISION

Client makes
decisions based
upon its needs and
how it wants to
structure its
pharmacy benefit.

#### PLAN DESIGN

Client makes the final decision about the drug benefit plan. PBM provides options based on client's unique needs, but client makes all the decisions.











# **Complex Market Dynamics Create Challenges** for Pharmacy and Whole Health Management

Rising Pharmacy Costs Population Health Management

Fragmented Care

Increased Consumerism

Lack of Effective Member Engagement

\$45B

per year could be saved through better care coordination<sup>3</sup>



### Proven Value of PBMs in Medicare Part D

The Government Accountability Office (GAO) released a PBM report<sup>1</sup> in July 2019 on how Part D plans are utilizing PBMs to gain value:

- Plans rely on PBMs. Part D plans used PBMs to provide 74% of drug benefit management services.
  - Drug benefit management services include: negotiating rebates, establishing pharmacy networks, formulary development, management of a Pharmacy & Therapeutics Committee, utilization management (a process to ensure that drug use is based on medical necessity, efficiency, and appropriateness), claims adjudication, enrollment processing, enrollee appeals and grievance process management, customer service, coordination with other drug benefit programs, and pharmacy technical assistance.
- PBMs pass through rebates. PBMs negotiated approximately \$18 billion in rebates from drug makers for Part D plans and passed through 99.6% of those dollars.
- Rebates are used by plans to lower premiums. This is why Part D premiums have remained flat.
  - Premiums were relatively unchanged between 2010-2015, even though total gross Part D drug costs grew 12% in that same period.
- The amount of rebates and other price concessions is growing rapidly. From 2014 to 2016, rebates and other price concessions increased from \$17.5 billion to \$29 billion a 66% increase showing the value PBMs provide in lowering costs.



#### **Molina Healthcare of Florida**

# **Developing the Formulary**

	Florida	New York	South Carolina
		Molina sets the	Molina sets the
	AHCA sets the formulary, the criteria and gets all rebates.	formulary, the criteria	formulary, the criteria
Medicaid		and gets all rebates	and gets all rebates,
		except HIV, which are	which are accounted for
		accounted for in rates.	in rates.
	Molina sets the formulary, the criteria and gets all of the rebates to help reduce premiums.	Molina sets the	Molina sets the
		formulary, the criteria	formulary, the criteria
Marketplace		and gets all of the	and gets all of the
ivial ketplace		rebates which are	rebates which are
		applied to reducing the	applied to reducing the
		premiums	premiums
	Molina selects one of		
Medicare	the formularies that is provided by the PBM	N/A	N/A



## One Driver of Cost Increase in Pharmaceutical Spend

2010 <sup>1</sup>			
Rank	Drug	Worldwide Sales	
1	Lipitor	\$10.7B	
2	Plavix	\$9.4B	
3	Advair	\$8.3B	
4	Enbrel**	\$7.3B	
5	Humira**	\$6.5B	
6	Zyprexa	\$5.0B	
7	Nexium	\$5.0B	
8	Singulair	\$5.0B	
9	Seroquel	\$5.0B	
10	Lovenox	\$3.6B	
Total Top 10		\$65.8 <b>B</b>	

2018 <sup>2</sup>				
Rank	Drug	Worldwide Sales		
1	Humira**	\$19.9B		
2	Eliquis	\$9.9B		
3	Revlimid	\$9.7B		
4	Opdivo	\$7.6B		
5	Keytruda	\$7.2B		
6	Enbrel**	\$7.1B		
7	Herceptin	\$7.0B		
8	Avastin	\$6.8B		
9	Rituxan	\$6.7B		
10	Xarelto	\$6.6B		
Total Top	10	\$88.5 <b>B</b>		

#### Pharma's TV advertising spend increased about 8% in 2018 to \$3.73B1

Rank	Drug Name	Use	TV Ad Spend	% of Spend
1	Humira	inflammatory conditions	\$375M	10.0%
2	Lyrica	neuropathic pain	\$213M	5.7%
3	Xeljanz	inflammatory conditions	\$209M	5.6%
4	Trulicity	diabetes	\$183M	4.9%
5	Xarelto	prevent blood clots/stroke	\$143M	3.8%
6	Otezla	inflammatory conditions	\$139M	3.7%
7	Eliquis	prevent blood clots/stroke	\$136M	3.6%
8	Keytruda	oncology	\$107M	2.9%
9	Ibrance	oncology	\$92M	2.5%
10	Jardiance	diabetes	\$86M	2.3%



#### Molina Healthcare of Florida

# Policy Areas which Can Cause Member Disruption and Pharmacy Hardships:

- **Transitional fills** State PDL conflicts with continuity of care. If we comply with the PDL and use a name brand, we increase costs. If we keep the original, we get audited.
- **Immediacy of Fills** Some member with (i.e Cystic Fibrosis) prevent them from being able to endure a lag-time till a pharmacy can be located that has brand on hand. Also, transport issues come into play as well.
- **Flu Season** Tamiflu treatment should begin within 48-hours. During a brand name shortage, we allowed generics to pay. Again we were audited for non compliance of the formulary.
- **FL Generics Law** Many pharmacist are hesitant to dispense a BRAND when a generic exists based on FL generics law. If prescriber did not indicate DAW OR BRAND NAME ONLY.
- Burden of Brand Name Requiring Brand prescriptions can cause hard ship on Independent Pharmacies increasing their inventory



# **Questions or Comments?**









#### Michael Jackson, B.Pharm, C.Ph. Executive Vice President and CEO, Florida Pharmacy Association

Michael has been a licensed pharmacist in both Florida and Alabama for over 40 years. His practice experience includes independent and chain pharmacy as well as hospital and veterinary hospital pharmacy. He has management experience including responsibilities of over 58 pharmacies in the states of Florida, Alabama and Mississippi. He has also served on various state councils and boards including the Drug Utilization Review Board (Florida Medicaid), Collaborative Drug Therapy Management Task Force, Florida Health Insurance Advisory Board, Florida Commission on Excellence in Health Care (2001), ePrescribe Florida Advisory Council, Florida Health Information Exchange Coordinating Committee, Florida Governor's Health Information Infrastructure Advisory Board, the Florida Agency for Health Administration Electronic Prescribing Advisory Panel, and the Florida Department of Environmental Protection-Biomedical Pharmacy Technical Advisory Committee.

Michael also served 3 years in academia coordinating the professional experiential learning program at Florida A&M University as well as teaching and pharmacy practice responsibilities at Tuskegee University's College of Veterinary Medicine. He has published over 400 articles and newsletters and has been quoted in several national publications. Michael is currently the Executive Vice President and Chief Executive Officer of the Florida Pharmacy Association and is past president of the National Alliance of State Pharmacy Associations.



Unifying and strengthening the voice of pharmacy while advancing pharmacy practice through education, advocacy collaboration, and relationships

November 4, 2019

Senator Doug Broxson, Chair Senate Banking and Insurance Committee 404 S. Monroe Street Tallahassee, FL 32399-1100

Re: Pharmacy Benefit Manager Impact on the Pharmacies and Patients

Dear Senator Broxson,

Thank you for allowing us to provide comment to the Banking and Insurance Committee on Pharmacy Benefit Manager (PBM) issues. Our membership includes community, hospital, consultant and long term care pharmacists as well as pharmacists in government service, academia and a variety of other practice settings. Our organization has as our membership a number of professional pharmacy students, technicians as well as individuals who do not have a formal pharmacy training background but have an interest in the practice and business of pharmacy. There are also over 18 regional and local pharmacy organizations that are affiliated with the Florida Pharmacy Association. Issues related to revisions of public policy are routinely shared with these organizations.

The Florida legislature will be facing a wide variety of health policy proposals across interest groups. In many cases the most significant challenges for Florida will be those related to cost and quality of health care. This by far represents one of the biggest tasks that the Senate Banking and Insurance Committee must deal with when running a state the size of ours. Evidence shows through various studies that pharmacists help to lower health care costs as well as improve the proper utilization of prescription drugs and

devices. Our services in our state's licensed pharmacies go far beyond the processing of prescriptions or medication orders. We are charged with the responsibility of ensuring that the drug product selected is appropriate for each patient. Some medications that are given together may cause undesirable effects. When we provide medications to patients we search for problems related to drugs interacting with each other, diseases and drugs that should not be combined or problems related to taking drugs with certain foods.

There is a pharmacy within 5 miles of every household in America. Nearly every citizen of this state will visit a pharmacy each month. Florida licensed pharmacists are available for health care consultations evenings, nights, weekends and holidays. Most do not even require an appointment. We are this state's most accessible health care professional working hard to solve the health needs of Florida.

Changes in Florida laws approved by the legislature and signed by previous governors allow pharmacists to immunize adult patients for influenza, pneumonia, shingles as well as a host of other vaccine preventable diseases recommended by the Center for Disease Control and Prevention. Well over millions of doses of flu vaccines have been administered to patients who probably would not have received a flu shot otherwise.

Having shared the above with the Committee it is important to note that our industry is also besieged by an unregulated third party middle man that has created negative disruption within the pharmacy small business community and taken away consumer choice. That entity is called a pharmacy benefit manager (PBM). Florida laws define a pharmacy benefit manager as a person or entity doing business in this state which contracts to administer prescription drug benefits on behalf of a health insurer or health maintenance organization to residents of this state. Nearly every prescription provided to consumers in this state must come through a pharmacy benefit manager or PBM. There is not much known about this industry which also means there is a lot of confidential information related to prescription drug costs that the public does not have access to. Just recently states like Ohio have been looking into PBM practices and found over \$220 million in overbilling of Medicaid by pharmacy benefit managers. That excess billing costs taxpayer dollars that could have been used for other essential state health care services. With Florida being a much larger state the scale of this problem could be greatly magnified.

Here in Florida the legislature began looking at the PBM marketplace when it was discovered that pharmacy providers were being prohibited from sharing information with patients about lower cost alternatives for their prescription medications. House bill 351 was adopted in 2018 to prohibit plan contracts with PBMs from interfering with a pharmacist's obligation to disclose lower cost options. Also over the years it was necessary to advocate for changes in Florida laws to create fair auditing standards. Unfair auditing procedures that were not clear to pharmacies resulted in massive paybacks to PBMs. In many of these cases not only was the pharmacy's fees taken away but also the cost of the prescription drug that the pharmacist legally dispensed to a patient for a drug prescribed by a physician and paid for by the pharmacy.

Pharmacies today are also not clear on how pricing is being determined and what they are being paid for their services. There is no other health care provider that we are aware of which operates in an unknown reimbursement space like this. Certain prescription drugs are placed into what is known as a maximum allowable cost (MAC) price list that is supposed to be updated regularly however there is no way to validate that is being done and no method in place for a pharmacy to seek relief when there is belief that a MAC list is noncompliant. Pharmacies are being told that the method to determine a MAC price is confidential and cannot be disclosed.

Perhaps it may be easy under some business practices to simply elect to disagree with the terms and conditions of a managed care or PBM contract but in reality the options are to either accept or not accept a contract in its entirety. This can be devastating for pharmacy businesses in areas dominated by a single PBM.

For the past several years we believe that pharmacy providers have been subsidizing the costs of prescription drug health care. It has created an unhealthy market place for consumers and to some extent, we believe that eventually it could create some access and cost issues for consumers particularly in medically underserved areas of Florida if a pharmacy continues to provide services below their costs.

Our members are working hard to provide medication management services for the patients in their communities. These pharmacies have cared for these patients for many years and have managed the health of not only those patients but their family members as well. Florida based pharmacy businesses are locally owned and operated and pay taxes and fees for the privilege of serving their communities. Taxes and fees paid by


Florida based pharmacy businesses and Florida licensed pharmacy personnel are used to fund the very health care support programs used to treat the indigent and underserved. Many of these Florida based businesses are supporting their communities through sponsorship of local charities and events and are contributing to the creation of jobs and the local economy. They have a corporate footprint on Florida soil but in some cases they may be shut out of networks and banned from helping those who cannot help themselves. Pharmacies that can provide the credentials show the quality of care and are willing to accept the terms and conditions of a managed care contract should not simply be brushed off as an undesired provider of pharmacy services.

On behalf of the many thousands of pharmacy stakeholders I want to thank you for allowing us to provide these comments and I am available to answer any questions that you may have.

With kindest regards,

Michael a. Jackson

Michael A. Jackson, BPharm EVP & CEO



#### Steven McCall, R.Ph., M.B.A. Vice President of Network Services, CVS Caremark


Steven McCall is the Vice President of Network Services for CVS Caremark. His responsibilities include overseeing the audit and pharmacy credentialing functions.

Steve started as a pharmacy technician over 30 years ago in a small independent pharmacy in Washington State. Following graduation, he took a job as a retail pharmacist servicing patients in Central Florida. He later moved on to a closed door pharmacy in Arizona servicing LTC, Assisted Living and Hospice populations. Steve attended business school and worked as the Director of Pharmacy for a small hospital corporation with financial responsibility for four locations. He later worked for 4 years as a clinical team leader and dispensing pharmacist with a national home infusion/specialty pharmacy. Steve has been in the field of pharmacy since 1987 and licensed as a pharmacist for 24 years.

Steve has a degree in Pharmacy from Washington State University and a MBA degree with a concentration in Services Marketing and Management from Arizona State University. He is a member of the National Healthcare Anti-Fraud Association (NHCAA) and the National Association of Drug Diversion Investigators (NADDI).



# Integrated Audit Solutions to Help Mitigate Fraud, Waste and Abuse



- Multiple levels of review to help curb waste and educate pharmacies on proper claims submission
- Continuous monitoring identifies suspicious claims patterns
- Inappropriate
   activities addressed
   through plan edit
   enhancements or
   law enforcement

In 2018, Pharmacy Audits Educated more than 70% of Network Pharmacies



# Daily Reviews - How they work

Pharmacy Submits claim for medication to Caremark through adjudication



Claims are run through a pharmacist created algorithm based on normal dosing



Audit team reviews outliers and calls pharmacies for the directions to determine if claim was submitted correctly



Pharmacy is requested to correct an errors on the claims submission.

Pharmacist Reviews claims that were correct



# **Daily Claims Review - Benefits**

- Daily Reviews are designed to validate claims submissions with minimal impact
- Designed to be invisible
  - Pharmacy has a chance to correct claims errors before they are impacted financially
  - Members are not aware that pharmacy made an error in the billing avoiding questions as to pharmacy quality and harming the pharmacistpatient relationship
  - Plan sponsors do not have to wait for financials to be corrected without an onsite audit
- Daily Reviews audits key off of red flags that could lead to an onsite or investigational audit thus reducing likelihood of further audit efforts
- Great educational opportunity for pharmacies to improve processes



Pharmacy Submits claim for medication to Caremark through adjudication





All claims are pulled for a pharmacy and compared against rules versus the pharmacy's peer group creating risk score



Onsite auditor pulls claims profile using risk score. Claims are selected for review of the submission versus the hard copy



Auditor performs an onsite visit to audit claims and educate pharmacy on proper submission techniques





## **Onsite Audits**

CVS Caremark plan sponsors want to insure that a sample of pharmacies are visited in person to compare hard copy prescription with the information submitted by the pharmacy.

These audits are designed to be approximately 60 - 90 minutes and not disrupt patient care. They have a large educational component so any discrepancies found can be understood to prevent re-occurrence and charge backs.



# Proactive Approach to Education of Network Pharmacies

Audit Tips distributed to Pharmacies, Chains, and PSAO's to inform pharmacists of common errors seen in the marketplace and trends

Provider Manual lists medications with unusual submission and details regarding the requirements of claim submission and expectations related to audit

Education and exit interview provided at end of each onsite and investigative audit to answer all pharmacy staff questions related to accurate claims processing and review discrepancies noted in audit

Meetings with chain and PSAO affiliations to address audit findings and provide tips

Continuing Education presentations to pharmacists and technicians in network pharmacies on accurate claim transmission and audit preparation



### Dr. Scott McClelland , Pharm.D., R.Ph, CHIE Vice President, Commercial and Specialty Pharmacy, BCBS

Dr. Scott McClelland is Florida Blue's Vice President of Commercial and Specialty Pharmacy. In his role, he is responsible for leading the pharmacy unit as well as the oversight and development of the clinical and operational strategy for the traditional, specialty and medical pharmacy areas, to ensure members have access to clinically sound and affordable pharmacy benefits and programs.

Prior to joining Florida Blue in 2006, Dr. McClelland held a leadership position within the HCA Hospital System as the Manager of Pharmacy Operations. He has over 20 years of experience as a clinical pharmacist specializing in critical care hospital based medicine and pharmacy benefit management.

Throughout his career, Dr. McClelland has been active in community and professional organizations. He is a member of the Academy of Managed Care Pharmacy (AMCP); America's Health Insurance Plans (AHIP); American Society of Health-System Pharmacist (ASHP); and has served as adjunct professor to several university systems.

Dr. McClelland received his Bachelor of Science and Doctorate of Pharmacy degree from the University of Georgia. In addition, he completed an ASHP Pharmacy Practice Residency, received his Health Information Certification from the Blue Cross Blue Shield Association and was certified as a health insurance executive through America's Health Insurance Plans (AHIP) leadership program.

### LuGina Mendez-Harper, PharmD, RPh State Government Affairs Principal, Prime Therapeutics

LuGina Mendez-Harper is a State Government Affairs Principal with Prime Therapeutics. She has been a pharmacist for over 20 years and has worked in a variety of clinical, administrative, regulatory, and legislative settings. She earned her Bachelor of Science degree in Pharmacy at the University of New Mexico. She obtained her Doctor of Pharmacy degree Magna Cum Laude from the University of Kansas. She also completed a Post-Doctoral Fellowship at Rutgers University and Bristol-Myers Squibb in Pharmacy Education and Drug Information.

Dr. Mendez-Harper has held positions in various aspects of pharmacy including the national association of pharmacists, community pharmacy, mail service pharmacy, specialty pharmacy, Indian Health pharmacy, and managed care pharmacy. Dr. Mendez-Harper served on the New Mexico Board of Pharmacy for 6 years and serves in various district and national state board of pharmacy association leadership roles. She is currently a member of the Accreditation Council for Pharmacy Education (ACPE) Board of Directors and Board liaison to the ACPE International Commission. She was appointed to the ACPE Board of Directors as the National Association of Boards of Pharmacy. ACPE assures and advances excellence in pharmacy education both with professional pharmacy degree programs and pharmacy continuing education providers. In her current role as State Government Affairs Principal with Prime Therapeutics, Dr. Mendez-Harper covers legislative and regulatory activities impacting all areas of pharmacy in 9 states including Florida.




# The Role of Pharmacy Benefit Managers in the Private Insurance Market

Florida Senate Banking and Insurance Committee Meeting

November 5, 2019

LuGina Mendez-Harper, PharmD, RPh Government Affairs Principal




# What is a Pharmacy Benefit Manager (PBM)?

### **Pharmacy Benefits Manager - PBM**

A health care company that contracts with plan sponsors (insurers, self-funded employers, unions, and government programs) to administer the prescription drug portion of the health

care benefit



# Who do Pharmacy Benefit Managers (PBMs) Work For?









## The Value of Pharmacy Benefit Managers (PBMs)



# Pharmacy Benefit Manager (PBM) Core Services



Claims Processing



Formulary Management



Drug Utilization Review



Disease
Management and
Adherence
Initiatives



Price, Discount and Rebate Negotiations with Pharmaceutical Manufacturers and Pharmacies



Pharmacy Networks



Mail-service Pharmacy



Specialty Pharmacy

5

# The Plan Sponsor Request For Proposal (RFP) Process

#### **Plan Issues RFP**

Request for Proposal (RFP) dictates the terms and conditions of the PBM services

### **Multiple PBMs Bid**

Highly competitive environment with bids from multiple PBMs

PBMs offer various design models depending on plan sponsor's specific needs

### **Plan Decision**

Plan sponsor may utilize benefit consultants

Decisions often reflect need of a robust pharmacy benefit that delivers cost savings


### **Plan Design**

PBM provides options based on the plan sponsor's unique needs

Plan sponsor makes the final decision about the drug benefit plan


6

# **The Drug Supply Chain**



# Pharmacy Benefit Managers (PBMs) in the Drug Supply Chain

PBMs Generate Savings for Plan Sponsors by Negotiating Discounts with Pharmacies and Rebates from Brand Name Drug Manufacturers



# Pharmacy Benefit Managers (PBMs) and Pharmacies



- Pharmacies may contract directly with PBMs
- Over 80% of independent pharmacies delegate contracting with a PBM to a Pharmacy Services Administrative Organization (PSAO)
  - PSAOs aggregate buying power of independent pharmacies to negotiate contracts with PBMs and other third-parties
  - Pharmacies may also delegate other services to PSAOs such as MAC appeals, drug purchasing, payment, and audits
- PBMs have no insight into private contracting terms between PSAOs and pharmacies

### **Drug Wholesalers Own 3 Largest PSAOs**

#### Pharmacy Franchise and Marketing Programs, 2016



McKesson's PSAO – HealthMart Represents More Pharmacies Than Wal-Mart

# Pharmacy Benefit Managers, Manufacturers, and Plan Sponsors


- Only if a brand name drug has clinically equivalent competitors can a PBM negotiate rebates with manufacturers in exchange for preferred formulary placement
- Pharmacy Benefit Managers pass rebates to the plan sponsor who uses it to lower the cost of the benefit (i.e., premiums)
  - The plan sponsor dictates exactly how the rebate is shared
  - The plan sponsor retains full audit rights in their PBM contracts ensuring transparency



### Pharmacy Benefit Managers (PBMs) Delivering Value

PBMs save plan sponsors and consumers an average of 35% compared to expenditures made without pharmacy benefit management






Source: Visante, prepared for PCMA. February 2016.

# There Is No Correlation Between Rebates and Drug Prices

- Drug manufacturers control, set, and change the price of their drugs
- Plan sponsors and Pharmacy Benefit Managers (PBMs) have no control over the price a manufacturer sets for a drug – but PBMs have some tools to drive down drug costs
- Until other drugs are approved for the same disease/condition, manufacturers have little incentive to reduce their prices
- Analysis of top brand name drugs by total spending between 2012 and 2017 showed the list price of drugs did <u>not</u> correlate with rebates



Source: PCMA and Visante analysis of data from CMS and SSR Health, 2018.

13

# The Role of Pharmacy Benefit Managers (PBM's) in the Health Care System

- Plan sponsors are not required to use a PBM, most do because PBMs drive adherence, hold down costs, and increase quality
  - PBMs help save plans 40-50% over unmanaged benefits<sup>1</sup>
- PBMs work for plan sponsors to exert downward pressure on prescription drug costs
  - PBMs are expected to save \$654B nationally in 10 years<sup>2</sup>
- Plan sponsors always have the final say when creating drug benefits
  - There is no one-size-fits-all model each plan sponsor has unique needs

2 Visante, Generating Savings for Plan Sponsors, Feb. 2016, available at: - <a href="https://www.pcmanet.org/wp-content/uploads/2016/08/visante-pbm-savings-feb-2016.pdf">https://www.pcmanet.org/wp-content/uploads/2016/08/visante-pbm-savings-feb-2016.pdf</a>

<sup>1.</sup> Visante, Return on Investment on PBM Services, Nov. 2016.

2. Visante, Generating Savings for Plan Sponsors, Feb. 2016, available at: - https://www.ncmanet.org/wp-col



## Thank you

LuGina Mendez-Harper, PharmD, RPh Prime Therapeutics Government Affairs Principal

Imendezharper@primetherapeutics.com

Cellular Telephone: 505-206-1089

### APPEARANCE RECORD

Meeting Date	copies of this form to the Senat	ol of Senate Professional Stat	Bill Number (if applicable)
Topic PRESENTATION ON THE	NOLY OF PHARMACY	BENEFIT MANAGER	Amendment Barcode (if applicable)
Name MICHAR JACKSON			
Job Title VP & CEO	447		•
Address 610 N. ADAMI	JT		Phone (850) 222-2400
Street TAUANANET	FL	32301	Email_MJACKSON@PHARMVIEW.W
Speaking: For Against	State  Information	<sup>Zip</sup> Waive Sp (The Chair	eaking: In Support Against will read this information into the record.)
Representing Florion	PYANMACY BS.	SOCIATION	
Appearing at request of Chair:	Yes X No		ered with Legislature: Yes No
While it is a Senate tradition to encourameeting. Those who do speak may be	age publić testimony, til	me may not permit all parks so that as many p	persons wishing to speak to be heard at this persons as possible can be heard.

S-001 (10/14/14)

This form is part of the public record for this meeting.

### APPEARANCE RECORD

(Deliver BOTH copies of this form to the Senator or Senate Professional Staff conducting the meeting)

Novamber 5, 2019  Meeting Date  (Deliver BOTH copies of this form to the Senato	r or Senate Professional Staff conducting the meeting)
Mooting Date	Bill Number (if applicable)
Topic PBM Worldshop	
Name Barney Bishop II	Amendment Barcode (if applicable)
Job Title Chief Executive Office - Bar	ney Bishop Consulting
Address 2215 Thomasville Road Street	Phone 850,510,9922  Barreye
Tallahassee FL City State	32308 Email Barneye Zip Email Barney Bishop.com
Speaking: For Against Information	Waive Speaking: In Support Against (The Chair will read this information into the record.)
Representing SPAR-Small Business Ph	varuacies Aligned for Reform
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature: Ves No
While it is a Senate tradition to encourage public testimony, time meeting. Those who do speak may be asked to limit their remark	may not permit all persons wishing to speak to be heard at this as so that as many persons as possible can be heard
This form is part of the public record for this meeting.	S-001 (10/14/14)

## APPEARANCE RECORD

(Deliver BOTH copies of this form to the Senator or Senate Professional Staff conducting the meeting)

Meeting Date	Staff conducting the meeting)
Weeting Date	Bill Number (if applicable)
TopicPBM	A
Name Scott Medelland	Amendment Barcode (if applicable)
Job Title PARMAY Programs Florida Blue.	·
Address USOO Decrivood Compus	Phone 904-905-1133
Sec (smulle 1-2 3224) City State Zip	Email Scott. McClelland @ bebsfl. com
Speaking: For Against Information PAMP Waive Speaking:	peaking: In Support Against ir will read this information into the record.)
Representing Florida Blue	, 
While it is a Senate tradition to encourage public testimony, time many at the second	ered with Legislature: Yes No
While it is a Senate tradition to encourage public testimony, time may not permit all meeting. Those who do speak may be asked to limit their remarks so that as many p	persons wishing to speak to be heard at this persons as possible can be heard.
This form is part of the public record for this meeting.	S-001 (10/14/14)

Meeting Date (Deliver BOTH copies of this form to the Senate	or or Senate Professional Staff conducting the meeting)
	Bill Number (if applicable)
Name Tom Brownhie	Amendment Barcode (if applicable)
Job Title Sinier Director	
Address 235 & Y2 Street	Phone 6/7-958-9983
Speaking: For Against Information	Zip Email Home Job vounter P  Zip Phone Job vounter P  Waive Speaking: In Support Against  (The Chair will read this information into the record.)
Representing PFizar	
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature: Yes No
While it is a Senate tradition to encourage public testimony, time meeting. Those who do speak may be asked to limit their remark.	
This form is part of the public record for this meeting.	S-001 (10/14/14)

(Deliver BOTH copies of this form to the Senator or Senate Professional Staff conducting the meeting)  Meeting Date
Bill Number (if applicable)
Topic PHARMACY BENEFIT MANAGERS
Name TRICIA FITZSIMMONS  Amendment Barcode (if applicable)
Job Title Director, Public Policy
Address One Health Plaza Phone 609-955-2909
East Hanover NJ 07920 Email tricia fitzsinmonse
Speaking: For Against Information Waive Speaking: In Support Against (The Chair will read this information into the record.)
Representing Novaris
Appearing at request of Chair: Yes No Lobbyist registered with Legislature: Yes No While it is a Senate tradition to encourage public testimony, time may not permit all persons wishing to speak to be heard at this meeting. Those who do speak may be asked to limit their remarks so that as many persons as many persons as many persons as many persons.
that as many persons as possible can be heard.
This form is part of the public record for this meeting.  S-001 (10/14/14)

# APPEARANCE RECORD

(Deliver BOTH copies of this form to the Senator or Senate Professional Staff conducting the meeting)

	tor or Senate Professional Staff conducting the meeting)
Meeting Date  Topic Presentation on the Role of Pharmocy be	Bill Number (if applicable)  Profit L Managers in the Private Amendment Barcode (if applicable)
Name	Insurance Market
Address 1337 US Hwg 90 West	Phone 856 - 892- 6898
Defunial Springs FL 32433 City State  Speaking: Against Information	Zip Email Preser, ptionplace O yahoo com
Representing	(The Chair will read this information into the record.)
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature: Yes No
	e may not permit all persons wishing to speak to be heard at this rks so that as many persons as possible can be heard.
This form is part of the public record for this meeting.	S-001 (10/14/14)

(Deliver BOTH copies of this form to the Senator or Senate Professional Staff of	conducting the meeting)
Meeting 'Date'	Bill Number (if applicable)
Topic Role of PBM in Insuvance	Amendment Barcode (if applicable)
Name Jacqueline Jacobi	
Job Title Regional Director of Pharmacy for Molina +	tealthcare
	hone 607-145-649
March M.	mail Jjacobi 6913@twc.com
Speaking: For Against Information Waive Spea	king: In Support Against Il read this information into the record.)
Representing Molina Heathcare	
Appearing at request of Chair: Yes No Lobbyist registere	d with Legislature: Yes No
While it is a Senate tradition to encourage public testimony, time may not permit all permeeting. Those who do speak may be asked to limit their remarks so that as many pers	sons wishing to anadata ha ha all the
This form is part of the public record for this meeting.	S-001 (10/14/14)

	r or Senate Professional Staff conducting the meeting)
Meeting Date	Bill Number (if applicable)
Topic	Amendment Barcode (if applicable)
Name Steve M Call R.	Harrie Lander La
Job Title VP, Notwork Service	
Address 950 E Shea Blac	Phone 480-614-7326
Street Scottsdale A	85213 Email
Speaking: State  Against Information	Waive Speaking: In Support Against (The Chair will read this information into the record.)
RepresentingCVS Health	
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature: Yes No
While it is a Senate tradition to encourage public testimony, tim meeting. Those who do speak may be asked to limit their rema	e may not permit all persons wishing to speak to be heard at this rks so that as many persons as possible can be heard.
This form is part of the public record for this meeting.	S-001 (10/14/14)

Meeting Date  (Deliver BOTH copies of this form to the Senator or Senate Professional Staff conducting the meeting)  Bill Number	(if applicable)
Topic Prescription Drug Panel Amendment Barcode	
Name Lu Gina Mondez Har per	
Job Title Govt Affairs Rineipal	
Address Phone 505-206-	1081
City State Zip  Speaking: For Against Information Waive Speaking: In Support (The Chair will read this information into the	Against Cov record.)
Representing	
Appearing at request of Chair: Yes No Lobbyist registered with Legislature:	es No
While it is a Senate tradition to encourage public testimony, time may not permit all persons wishing to speak to be he meeting. Those who do speak may be asked to limit their remarks so that as many persons as possible can be heard	
This form is part of the public record for this meeting.	S-001 (10/14/14)

### **CourtSmart Tag Report**

Case No.: **Room:** KN 412 Type: Caption: Senate Banking and Insurance Committee Judge:

Started: 11/5/2019 2:03:23 PM

Ends: 11/5/2019 3:59:13 PM Length: 01:55:51

2:03:22 PM Meeting called to order. Roll call

2:03:33 PM Quorum is present

2:03:52 PM Chair Broxson intro and recognizes Senator Rousson

2:04:25 PM Senator Rousson explains the purpose of the panel and discussion today

Senator Rousson introduces the order 2:07:03 PM

Chair Broxson gives direction on question and answer time 2:08:04 PM

Shane Abbot Pharmacist/ Pharmacy co-Owner of Defuniak Springs presents 2:08:38 PM

Chair Broxson with question to Mr. Abbott 2:18:46 PM

2:19:13 PM Mr. Abbott answers

2:20:31 PM Chair Broxson moves on to next speaker

2:20:50 PM LuGina Mendez Harper, Government Affairs Principal

2:21:46 PM Ms. Mendez Harper presents

Member questions 2:29:23 PM

2:29:36 PM Senator Rousson with question for LuGina Mendez Harper

2:30:01 PM Ms. Harper responds

2:30:20 PM Chair Broxson calls on Steve McCall R. Ph. VP Network Services of Scottsdale AZ for CVS He

2:31:47 PM Steve McCall presents information

2:36:20 PM Chair Broxson with comment about presentation

Mr. McCall responds 2:37:36 PM

Chair - with question 2:37:45 PM

Mr. Steve McCall 2:37:52 PM

Mr. Steve McCall 2:37:59 PM

Mr. Steve McCall 2:37:59 PM

Chair responds

2:38:06 PM 2:38:14 PM Steve McCall

2:38:24 PM Senator Gruters with question on audits

Steve McCall responds 2:38:36 PM

2:39:17 PM Senator Thurston with question on audit

2:39:44 PM Senator Thurston

Steve McCall answers 2:40:18 PM

2:40:25 PM Chair Broxson moves to next speaker Tom Brownlie

2:40:59 PM Tom Brownlie Senior Director of Pfizer from New York NY

Chair Broxson with question on price 2:42:18 PM

Mr. Brownlie with answer 2:43:20 PM

Chair Broxson with comments 2:46:47 PM

2:48:07 PM Senator Thurston with question

2:48:15 PM Tom Brownlie responds

2:49:28 PM Chair Broxson moves on to Jaqueline Jacobi

2:49:49 PM Jacqueline Jacobi Regional Director of Pharmacy for Molena Healthcare of Marietta NY

2:52:22 PM Chair Broxson

2:53:31 PM Next speaker is Tricia Fitzsimmons Director Public Policy of Novartis from East Hanover NT

2:54:33 PM Tricia Fitzsimmons presents

2:55:40 PM Chair Broxson

Tricia Fitzsimmons answers question 2:56:43 PM

2:57:16 PM Chair Broxson

2:58:50 PM Tricia Fitzsimmons

2:58:58 PM Senator Rousson with question 2:59:25 PM Tricia Fitzsimmons responds

2:59:42 PM Senator Thurston with question about list price

2:59:55 PM Tricia answers

3:00:13 PM Senator Thurston question about PBM

3:00:29 PM Tricia Fitzsimmons responds

```
3:00:57 PM
               Chair Broxson moves on to Scott McClelland VP Pharmacy Programs Florida Blue Jacksonville FL
               Scott McClelland Vice President Pharmacy Programs Florida Blue of Jacksonville FL
3:01:55 PM
3:05:03 PM
               Chair Broxson with question on PBM discounts
               Scott McClelland answers
3:06:04 PM
               Chair Broxson
3:06:13 PM
               Scott McClellan
3:06:15 PM
3:06:54 PM
               Senator Rousson
3:07:15 PM
               Michael Jackson is next speaker
               Michael Jackson Executive Vice President & CEO Florida Pharmacy Association
3:07:43 PM
3:11:41 PM
               Chair Broxson with question
3:12:46 PM
               Michael Jackson responds
3:12:59 PM
               Chair Broxson on secrecy
3:13:11 PM
               Michael Jackson responds
3:15:03 PM
               Chair Broxson opens for comments
               Senator Thurston for Mr. Jackson on DIR fee
3:16:11 PM
               Mr. Jackson responds
3:16:30 PM
               Chair Broxson
3:18:16 PM
               Senator Thurston follow up question
3:19:17 PM
3:19:33 PM
               Chair Broxson
               Michael Jackson responds
3:19:36 PM
               Chair Broxson questions Senator Lee
3:20:52 PM
3:21:12 PM
               Senator Lee with answer
               Chair Broxson follow up question to Tricia Fitzsimmons
3:23:48 PM
3:24:50 PM
               Tricia Fitzsimmons responds
3:25:15 PM
               Chair Broxson follow up to Tricia Fitzsimmons
               Tricia Fitzsimmons with suggestion
3:25:51 PM
3:26:44 PM
               Chair Broxson recognizes Senator Thurston
3:27:00 PM
               Senator Thurston with question on manufacture standpoint
3:27:40 PM
               Tricia Fitzsimmons responds
               Senator Taddeo with question
3:29:33 PM
               Tom Brownlie responds
3:30:13 PM
               Mr. Abbott to comment on discussion
3:32:02 PM
               Steve McCall comments on the same issue
3:33:49 PM
3:35:20 PM
               Chair Broxson with comment on the issue
               Mr. McCall comments
3:35:34 PM
3:35:45 PM
               Chair Broxson
               Senator Gruters with question
3:36:35 PM
3:37:05 PM
               LuGina Mendez Harper answers the question on rebates and PBMs
3:37:58 PM
               Chair Broxson with comment
3:39:21 PM
               LuGina Mendez Harper responds
3:39:54 PM
               Chair Broxson follow up
3:40:08 PM
               LuGina Mendez Harper responds
3:41:28 PM
               Chair Broxson
               Jacqueline Jacobi
3:41:37 PM
               Chair Broxson to Ms. Fitzsimmons -about rebates
3:42:04 PM
3:42:36 PM
               Ms. Fitzsimmons responds on negotiation
3:44:24 PM
               Senator Gruters with follow up question
3:44:39 PM
               Tricia Fitzsimmons
               Senator Lee is recognized
3:45:07 PM
               Jaqueline Jacobi - responds to Senator Lee question
3:46:49 PM
3:49:22 PM
               Tom Brownlie responds on same question
3:50:59 PM
               Chair Broxson with question
               Tricia Fitzsimmons to answer on value and delivery
3:51:26 PM
3:53:02 PM
               Chair Broxson
3:53:10 PM
               Question on insulin cost
3:53:25 PM
               Tom Brownlie responds
3:54:53 PM
               Chair Broxson opens for members to question
3:55:10 PM
               Senator Lee with question
3:56:04 PM
               Shane Abbott answers
3:56:42 PM
               Senator Lee
3:56:49 PM
               Shane Abbott
```

3:57:27 PM

Senator Lee

3:57:31 PM

3:58:01 PM

Steve McCall Chair Broxson wraps up Senator Perry moves we adjourn. The meeting is adjourned 3:58:30 PM

3:58:55 PM